Insmed Incorporated (NASDAQ:INSM) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET
Company Participants
Will Lewis – Chair & CEO
Sara Bonstein – CFO
Eleanor Barisser – IR
Conference Call Participants
Jeff Hung – Morgan Stanley
Andrea Tan – Goldman Sachs
Judah Frommer – Credit Suisse
Joseph Schwartz – SVB Securities
Liisa Bayko – Evercore ISI
Jennifer Kim – Cantor Fitzgerald
Operator
Good morning, and afternoon, and evening. My name is Darius, and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed Third Quarter 2022 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator instructions]
I now have the pleasure of handing over to your host, Eleanor Barisser from Investor Relations. You may begin your conference.
Eleanor Barisser
Thank you, Darius. Good morning, and welcome to today’s conference call to discuss our third quarter financial results for 2022, and to provide a business update. Before we start, let me remind you that today’s call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today, and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, which are available through the SEC’s website at www.sec.gov, or from our website for information concerning the risk factors that could affect the company. The information on today’s call is not intended for promotional purposes, and it is not sufficient for prescribing decisions.
Joining me on today’s call are members of the Insmed executive management team, including Will Lewis, Chair and Chief Executive Officer, and Sara Bonstein, Chief Financial Officer. Insmed’s business is currently comprised of four pillars, ARIKAYCE, Brensocatib, TPIP, and Translational Medicine. Let me now turn the call over to Will Lewis for prepared remarks. Upon completion of those remarks, we will open the call up for your questions.
Will Lewis
Thank you, Eleanor, and good morning, everyone. The third quarter of 2022 marked a major turning point for Insmed, as we advanced revenue growth, clinical trial enrollment, and secured meaningful financing. With approximately $1.3 billion in capital, we are now fully resourced to realize numerous clinical trial readouts from each of our four strategic pillars. Specifically, data from the frontline NTM program, Brensocatib in bronchiectasis, Phase 2 data from TPIP, in addition to anticipated IND filings, and preclinical and clinical data from our fourth pillar. Collectively, we believe these readouts will transform our company. Before providing detailed updates on our four pillars, I want to take a moment to discuss the recent financing. As I said last week when we announced the transactions, we have never been in a stronger position as a company. The strategic rationale of the financing was to raise needed capital to achieve our ambitious objectives, to mitigate some of the macroeconomic and geopolitical risks that continue to weigh on the markets, and to protect ourselves strategically as we advance our four pillars. This financing does not change our underlying strategy in any way. Rather, it places us in an enviable position against the backdrop of one of the more difficult market environments in recent history. Our aim was to catapult us past these concerns, and place us in a strong financial position in the future when we have what we hope will be positive results from each of our four pillars. We feel very good about the future of this company and the meaningful catalyst this financing will support, and that should be the takeaway message of these transactions. We look forward to updating you on our progress from here.
Turning back to this quarter’s performance. Sara will cover revenue in more detail, but the key takeaway is that our third quarter global revenue results were strong. We saw continued ARIKAYCE growth in the US, and despite COVID and foreign exchange headwinds in Japan, the region still meaningfully contributed to global revenues. Turning to Europe, we recently secured a favorable reimbursement approval for ARIKAYCE in England. With this decision, ARIKAYCE will now be commercially launched in all parts of the UK, as well as in Germany, the Netherlands, Italy, and Belgium. I remain very pleased with the performance of the commercial team globally, even as preparations are already underway for additional potential launches, including ARIKAYCE for Frontline NTM, and Brensocatib for bronchiectasis, if approved. Now, let me provide more detail on the clinical development activities within each of our four pillars, starting with the ARIKAYCE Frontline clinical program, which consists of ARISE and ENCORE, two global trials running in parallel. We believe results from these trials, if favorable, will support full FDA and select international approvals of ARIKAYCE for newly diagnosed MAC NTM patients. In the US in Japan, our two largest geographies, the number of newly diagnosed patients with MAC NTM, is approximately 115,000, and 145,000, respectively. While we work to refine those who are appropriate for immediate treatment, should we secure frontline approval, by any calculation, the expansion into Frontline would represent a multifold increase in our current addressable market. Screening is now complete in the ARISE trial, and I am pleased to report that enrollment is nearly complete. We anticipate the last patient will be enrolled in ARISE in the next two weeks, which is slightly ahead of schedule.
Let me provide some commentary on what you can expect from the ARISE trial results. We anticipate sharing a range of data from ARISE over the course of next year. To remind you, our goal with the ARISE data is, first, to demonstrate that the PRO is valid and responsive. We anticipate these data by the end of the first half of 2023. Next, we will examine the entire dataset, comparing the treatment and non-treatment arms using the PRO, as well as culture conversion, and other important measures. We anticipate sharing these data in the second half of 2023. With ARISE enrollment essentially complete, we anticipate the pace of enrollment in ENCORE to accelerate, with early signs suggesting this will be the case. We remain on track to complete enrollment in the ENCORE trial before the end of 2023, and look forward to updating you on the pace of enrollment as we move forward. Additionally, with the ARISE data, we hope to have a clear understanding of the likely performance of ENCORE. Should adjustments be necessary to ENCORE, we will have the time and opportunity to do so before the data readout, increasing our likelihood of success in this registrational study. We look forward to updating you on our progress in the frontline program.
I’ll now turn to our second pillar, Brensocatib, an oral DPP-1 inhibitor that we believe has enormous potential to treat an array of neutrophil-mediated diseases, thereby representing a potential pipeline in a product. If successful, we believe Brensocatib could be a groundbreaking addition to the anti-inflammatory treatment landscape. We are working to build a platform around this first-in-mechanism approach, and have settled initially upon four separate indications to pursue clinically, bronchiectasis, cystic fibrosis, or CF, chronic rhinosinusitis without nasal polyps, or CRS, and hydradenitis suppurativa, or HS. Starting with bronchiectasis, the encouraging pace of enrollment in our Phase 3 ASPEN trial continues, giving us confidence in our estimate of completing enrollment before the end of the first quarter of next year. With this target in mind, we are excited to share our expectation of topline data from the ASPEN trial in the second quarter of 2024. In addition, I am pleased to report that the third meeting of the Data Safety and Monitoring Board, or DSMB, occurred earlier this week where it was determined that the ASPEN study should continue as planned. If Brensocatib is approved by regulatory authorities for use in treating bronchiectasis, we plan to target approximately 1 million bronchiectasis patients at launch in three key geographies, the US, Europe, and Japan. Though bronchiectasis is a broader opportunity than NTM, the synergies between these indications are significant, and we expect to benefit from the overlap in call points, and be able to leverage much of the commercial infrastructure between these indications.
Let me now turn to the second potential indication for Brensocatib, cystic fibrosis. The Phase 2 PKPD study is advancing as planned, and we remain on track to have topline data by the end of this year for both patients on CFTR modulators, and those not on CFTR modulators. Recall that CF represents another sizable market opportunity, with an estimated 70,000 total diagnosed patients worldwide, and nothing approved to treat reduction of exacerbations in this population. As previously shared, we have identified two indications for further clinical development, CRS and HS. Importantly, like NTM in bronchiectasis, CRS is another condition where there is nothing approved for treatment. We plan to start a Phase 2 study in CRS in the middle of 2023. HS will follow thereafter. We’re pacing these studies mindfully in order to balance their potential against the cash burn increase they would represent while we await results from the ASPEN study. We believe the enormity of the unmet medical need that could be addressed by Brensocatib, cannot be overstated. Additional indications could add potentially millions of patients to the addressable market for this program. Our third pillar is TPIP, a treprostinil prodrug in Phase 2 development for pulmonary hypertension associated with interstitial lung disease or PHILD, and pulmonary arterial hypertension, or PAH. Both studies are enrolling patients and continuing to open sites. We anticipate both trials will accelerate their pace of enrollment as we enter 2023.
I’ll now turn to our fourth pillar, Translational Medicine. The work we are doing in this pillar will become increasingly important to Insmed’s long-term strategic vision, as it reflects compounds and technology platforms with the potential to have a profound impact on patients in the rare disease space. From this pillar, we intend to generate on average one to two INDs per year for the next several years. This pillar includes a world-class gene therapy group, in addition to novel methods of manufacturing that, if successful, we expect would lower the cost to produce gene therapies multifold. In addition, we are making progress using artificial intelligence and advanced capabilities in protein engineering to attempt to deimmunize the actual AAV caps used to dose patients with gene therapy, potentially enabling us to redose patients. Collectively, these technologies, if successful, could transform the gene therapy landscape, and we believe result in safer and more effective therapies at significantly reduced costs.
Finally, unrelated to gene therapy, we also have ongoing efforts pursuing specific deimmunized therapeutic proteins, where patients would benefit from redosing. We are planning a research day where we will delve into more details with you. We are finalizing a date for that to take place in the first half of next year. We look forward to sharing more on the teams and technologies behind these efforts over the coming months. Across all four pillars and around the world where we operate, Insmed is advancing like never before. We believe we are making great progress in achieving our ambition to build one of the next great biotechnology companies.
Let me now turn the call over to Sara for her commentary.
Sara Bonstein
Thank you Will, and good morning, everyone. As an outcome of our financing activities last week, we are in the strongest cash position in the company’s history. We are very encouraged by the interests and commitment from high quality healthcare investors and partners, and their support reflects their collective confidence in the future of Insmed. As a result, we now have the ability to fully realize value across our four pillars, test meaningful clinical readouts. Earlier today, we issued a press release with our detailed third quarter financial results, all of which are aligned with our internal expectations. Let me walk through a few of those results for you now. As reported this morning, we ended the third quarter with $513.3 million in cash and cash equivalents, and marketable securities. Subsequently, following the completion of our financing last week, we more than doubled our cash position, resulting in a pro forma balance of approximately $1.3 billion in cash and cash equivalents, and marketable securities. We have and plan to continue to manage this strong balance sheet, with a sharp focus on cash preservation, while mindfully investing in our pipeline. We expect that our runway will support meaningful shareholder value-creating opportunities across all of our programs.
In the third quarter of 2022, total net revenue for ARIKAYCE was $67.7 million, demonstrating the strongest quarter of sales since ARIKAYCE launched. Notably, total net revenue in the third quarter showed a 45% increase versus the third quarter of 2021. On a regional basis, net revenue in the third quarter was $49.5 million in the US, $14.5 million in Japan, and $3.7 million in Europe and rest of world. Specifically, in the US, we saw a 29% increase over prior years’ third quarter performance, showing continued overall growth in our largest market. In fact, this is our largest year-over-year percentage revenue growth since launch. The US market for ARIKAYCE has almost fully recovered from COVID in terms of our ability to achieve in-person office visits. We anticipate patients will continue to return to in-person doctor visits. And this, along with heightened physician suspicion of respiratory disease, could yield greater identification of appropriate patients who may have delayed their treatment during COVID.
Finally, we continue to see a trend in patients restarting their therapy. In Japan, we saw meaningful contribution, representing more than 20% of our overall global ARIKAYCE revenue. This is an extremely encouraging number, and a base from which we believe we can continue to grow. While we faced two headwinds in Japan in the third quarter, COVID restrictions, and the impact of foreign exchange rates, we remain very pleased with the fundamental performance from this market, and look forward to building on this strong foundation. We continue to anticipate a more modest revenue contribution from Europe relative to the US and Japan, and our commercial operations are scaled to reflect this. Importantly, Europe continues to be a key territory for clinical trial work, thought leadership engagement, and medical affairs activities. With a demonstrated track record of success, and a favorable growth profile, we believe there’s opportunity for further ARIKAYCE growth globally. We’ve clearly exceeded our revenue guidance of more than 30% for 2022, and we look forward to ending this year in this position of strength. Although the uncertainties of COVID and foreign exchange rates had a meaningful impact on the year, we are hopeful that these headwinds will be less prominent in 2023.
Let me now touch on some additional financial highlights from the quarter. In the third quarter of 2022, our gross to nets in the US were approximately 11%, which is in line with our guidance of mid-teens throughout 2022, and consistent with gross to nets in prior years. Cost of product revenues for the third quarter of 2022 was $13.5 million or 20% of revenue on a percentage basis. Turning to our GAAP operating expenses. In the third quarter of 2022, research and development expenses were $99.9 million, and SG&A expenses were $75.6 million, reflecting the support of our ongoing clinical trials, and the commercial infrastructure for ARIKAYCE. In closing, Insmed’s tremendous balance sheet strength provides us with ample runway at a crucial time as we continue executing across all of our pillars.
I’ll now turn the call back to Will for closing remarks.
Will Lewis
Thank you, Sara. Insmed has a vision to become one of the next great biotechnology companies. This is an ambitious goal. Hopefully, from today’s call, you can see how we have deliberately established the pieces to bring about this achievement. This quarter, we made another important step forward on this path, and we are now positioned and resourced as never before, supported by a team that is motivated to do the right thing to bring medicines to patients with serious and rare diseases. I would like to thank the patients who participate in our studies, the caregivers and families who support them, the Insmed team, and those who have sponsored us financially. This is a significant vote of trust and belief in our ambitious vision, and we are excited to deliver on this for all of you.
With that, I’d like to open the call to questions. Operator, can we take the first question, please?
Question-and-Answer Session
Operator
Yes. [Operator Instructions] The first question comes from Jessica Fye from JPMorgan. Please go ahead, Jessica.
Unidentified Analyst
Hey guys, this is Nick on for Jessica. Thanks for taking our questions and congrats on the quarter. Quickly, understanding that there was some stocking last quarter in Japan, given the two-week spending limit lift in 2Q, as well as FX headwinds and some COVID impacts, can you just talk to us a bit about how you’re thinking about growth in the region in 4Q and 2023? Should we be thinking about COVID more as a waning headwind and FX as more of a gaining headwind on this front?
Will Lewis
Thanks for the question. Actually, I think it’s really hard to answer that with any great clarity because the uncertainty that surround both of those variables. What I will say is that the performance side of Japan, at a fundamental level, the ability to have the product have impact on patients and the perception of physicians about its utility, is really strong. The ability to deliver the product is constrained by COVID as it surges and ebbs and flows. Clearly, it’s on, at the moment, a down slope, but it still takes some time to regain access to physicians and hospitals. As you know, they set aside beds for potential patient surges, those sorts of things. So, that has to all clear out. And as far as FX goes, I don’t think anyone would’ve expected us to be at 147 to the dollar, or wherever we are today. And it could get worse before it gets better. We just don’t know, and that makes it very difficult to sort of forecast with any accuracy or confidence what’s going to happen in Japan. I will just reemphasize that the fundamentals of that market are strong and we expect growth to come from Japan as we enter 2023.
Unidentified Analyst
Great. And then one last one. Have you decided – in the Phase 2 PKBD PD trial coming up for the end of the year, have you decided to dose up to the 65-milligram dose? And in particular, with the data coming, are you expecting any similar or different results between – striking similar or different results between the two arms consisting of those who are and aren’t on background CFTR modulators?
Will Lewis
Yes, so the – as to the second question, that’s really why we broke it out that way. We want to see if there’s any distinction between them. I don’t know that there is a reason to expect there to be, but of course, that market is segmented by those who are able to benefit from CFTR modulators and those who are not. And so, we want to just kind of have a look at that. Importantly, there’s nothing approved to treat exacerbations in CF patients regardless of the background therapy. So, this is another greenfield opportunity for us with this drug. In terms of where we’re going to go with doses, we have to look at the data first and then we’ll be able to give you some guidance on that, but we expect to have the data in hand by the end of the year to know what that’s going to look like.
Unidentified Analyst
Great. Thanks so much.
Operator
Our next question comes from Jeff Hung from Morgan Stanley. Please go ahead, Jeff.
Jeff Hung
Thanks for taking my questions. You reiterated ARIKAYCE guidance today. Can you just talk about the thinking for not raising guidance, since this implies that you could have a 13% sequential decline in 4Q and still meet your guidance? Like what factors should we think about in 4Q in any of the geographies that could lead to more modest outcome for fourth quarter? Like is it mainly FX, or are there any other things to consider?
Will Lewis
Yes. No, I think, look, the market is in an uncertain place at the moment. Having said that, I think each of our quarters this year, we’ve done a nice job in terms of performance. I expect the ARIKAYCE brand globally to continue to grow, whether that will be contributed to more or less from Japan, given the headwinds we just referred to, et cetera. As we were very clear about on the call today, the US is almost back to where it was pre-COVID. So, there are a lot of positives behind this brand. But the landscape before us, and this happened to also inform thinking about the financing, is just very uncertain. And so, I think we want to be cautious as we move forward. What we are focused on now is how we continue to grow this as we leave this year and enter next year. And I think that picture is a good one. I think the question of whether it will grow is not really what’s in my mind. It’s more a question of to what degree. And so, that’s where the uncertainties weigh in on our thinking, and caution is the watch word of the day.
Sara Bonstein
And Jeff, if I can just add on to that real quick. If you held FX constant from the January rates when we obviously came up with our guidance, the impact of that was – is over $10 million on what an annual basis would be for revenue. So, the fact that we’ve been able to continue to meet and exceed our guidance and be able to hold our guidance despite those headwinds, we’re really – we feel really confident in ARIKAYCE and what it’s been able to produce and what it has the ability to produce in the future.
Jeff Hung
Great. Thanks. And if I ask another one. For ARISE and ENCORE, you said that the PRO is more for the FDA than physicians, I believe. Has the agency indicated that a trend for one arm beating the other would be sufficient, or have they given more specificity of what they would like to see? Thanks.
Will Lewis
So, the first thing we have to do is validate the PRO, and that’ll happen in the first half of next year. Assuming that that goes as planned and the PRO is both responsive and tracks patients’ behaviors, then we’ll be able to make commentary on what is clinically meaningful in terms of a change within the use of that PRO. Once we’ve identified that, we’ll be able to compare the two arms and make, obviously, statements about the degree to which our drug has provided that benefit to patients. I’d say today, we feel pretty good about – while it’s all blinded still and we can’t see individual data, but the overall blended blinded data suggests to us that there is something going on within the trial. We know from our commercial experience that the use of the drug has certain benefits anecdotally from patients. We’ve been doing this for several years now, and that’s consistent with what we’re seeing in the blended data. So, my expectation is that we will see that this PRO is able to track change, and my expectation is that that will be in favor of the ARIKAYCE arm. To what degree, it’s hard to say, but I’m happy with what we’re seeing so far. FDA has not pre-specified what threshold we need to clear. That’s part of the reason for the ARISE trial is to sort of explore what the PRO may be able to track. And so, that’ll be subject to some dialogue.
Jeff Hung
Great. Thank you.
Operator
The next question comes from Andrea Tan from Goldman Sachs. Please go ahead, Andrea.
Andrea Tan
Hi, everyone. Thanks for taking my question. On the first one, maybe with respect to the recent financing deals, understand being opportunistic in this market, but just wondering if you could talk more particularly on the decision to monetize ARIKAYCE and Brensocatib royalties.
Will Lewis
Sure. So, the strategy there was to sort of look for ways to bring on capital in quantities so we could message that we are going to catapult past all these geopolitical and macroeconomic dislocations that may be operating in the market for some time. We wanted to do that not using exclusively permanent capital. And so, we looked at a wide variety of different approaches we could take, and we settled on accommodation of a royalty and the term loan. The royalty is very small, as you know, less than 5% on ARIKAYCE, and less than a point, 75 basis points on Brenso, and that’s assuming that it gets approved and moves forward. My expectation is that this will not be something that weighs on either product for very long. As you think about the repayment of this, it is a capped royalty, and that is probably the most important point to take away. This is a repayment of the royalty over a period of time, and once it’s done, it goes away for good. So, one of the things that was entering under our mind is to make sure that we don’t burden either of these assets for any extended period of time so that they continue to have real strategic value.
Andrea Tan
Got it. And then just a follow up to the prior question on ARISE and ENCORE. Just, can you remind us the nature of the changes you would be considering or you could make pending the PRO findings?
Will Lewis
Sure. So, when we look at this, the first thing we want to see, as mentioned, is the PRO responsive? For example, as we look at the different components of the PRO, cough, sputum expectoration, fatigue, do we see changes in those measures? Are those changes themselves at a level that is clinically meaningful, enough of a change? And then is that change associated with an overall feeling of betterment, so well-being? And if we see change and it’s associated with feeling – patients feeling better, then we know we’ve got a winner. And on that particular measure, let’s say it’s cough, cough improves dramatically and it makes patients feel better to cough less, we can track all of that and it’s better in the ARIKAYCE arm, that’s obviously something we want to make sure we are emphasizing in the ENCORE study. It may be that at the conclusion of ARISE, we don’t need to make a single change. I think the beauty of the design, if I can suggest it, is that we have the ability to make change should we come across unexpected outcomes. And such an unexpected outcome might be that cough is perhaps less dramatically impacted and something else is more dramatically impacted. And at that point, we could reconsider the statistical analysis plan to favor the measure of that particular impact greater.
Andrea Tan
Got it. Thanks so much.
Operator
The next question comes from Ritu Baral from Cowen. Please go ahead. Your line is now open.
Unidentified Analyst
Hi, guys. Thanks for taking the question. This is (Yanil) on for Ritu. I wanted to sort of understand if the Phase 2a TPIP PAH study, is it shut down? And do you have a PVR reduction goal at 16 weeks, given what you saw from the single patient that you’d reported previously?
Will Lewis
Yes. So, we did shut down the TPIP study, I think back in August, somewhere around that timeframe. But that was just an ongoing struggle. Again, nothing related to the product. This had everything to do with the difficulty of trying to find a volunteer who is very sick with PAH to undergo a 24-hour right heart catheterization. To get someone to submit to that became much more challenging than I think the original KOLs who designed the study thought it was going to. And so, we were only able to find one volunteer who was willing to do it. And at some point, we just said, we should be focusing on recruiting for the Phase 2b and Phase 2 PHILD and PAH studies directly, which are more traditional designs, should not encounter these kinds of delays because we’re not asking them to undergo this onerous procedure. To put a footnote on that, I don’t think anyone has ever done a right heart cath study that’s lasted more than about four hours. So, it was really quite a big ask, and I think we just missed that one based on the guidance we had gotten from KOLs. Having said that, we did manage to get one patient to volunteer. They did titrate up to 320 micrograms, with a once-a-day administration, and that is a significant achievement. We did see some important and positive trends in the performance of this patient. We’ve had a lot of reflection on whether or not it makes sense to put that data out. Because of the variability that surrounds these patients, while favorable, probably doesn’t make sense to put it out there and suggest that this is going to be the performance of every patient, but I would just tell you, we walk away very, very good, feeling very, very good about the potential of TPIP, the enthusiasm we have for these Phase 2 trials, and the fact that we can get somebody to 320 micrograms. I’ll just remind you, (Tamezo’s) max dose after titration in their label is 54 micrograms. So, we are well above what they are able to achieve. It’s not exactly apples to apples because they dose multiple times a day, but we are achieving our objective of getting more drug into the patient slowly released over time and over a 16-week time frame. That’s a beneficial impact for sure.
Unidentified Analyst
Thanks. And a quick follow-up on the TPIP program. Based on enrollment trends, should we expect data in 2024 from the other two TPIP studies that are ongoing?
Will Lewis
So, we haven’t given specific guidance on the two studies and when they’re likely to read out. My ambition is that the PHILD study will read out before the ASPEN data. And I think that’s a reasonable thing to assume. We’ll have more guidance on it once we get further into next year. That’ll be one of the updates we’ll be providing on where we’re going with those two studies. But PAH studies, this is a competitive space. Unlike all the other indications we’re pursuing, this actually does have products that are approved to treat it, but there’s a lot of enthusiasm from physicians. And so, I think we’re going to have some success in enrolling this, but we’ll have to see what that pace looks like.
Unidentified Analyst
Okay. And one last quick question. You had sort of spoken about your launch plans in the EU previously, and I just kind of wanted to know which territories were next. You listed a few that you had already completed toxin, or at least were advanced in, but what’s the ongoing progress and timeline of other countries being added for the …
Will Lewis
So, it’s really – yes, in the category of any day, I mean, important territories that remain are France. France is sort of notoriously unpredictable. As you may be aware, we’ve had a compassionate use program there under a particular program that they have for early access to drugs. It’s been very successful in treating patients, but it introduces uncertainty about when they will make their final decision, what that decision will look like with regard to reimbursement rates, et cetera. So, there’s more to be learned there. I would hope that will be in the not-too-distant future. But the trend we have so far in the territories where we do have approval, is quite positive. I think we found a good solution in Germany. I think we have a very strong position in the UK. And as you know, we got early access in the Netherlands under a special program, the first of its kind. So, there’s some positive there. Overall, the addressable market in Europe right now is roughly 1,400 refractory patients. So, it is not a large market opportunity. Patients are just diagnosed and treated differently in that region. Nonetheless, we think as we move through these approvals, it does two things. One, it lays the groundwork for some commercial contribution from that region to the overall global revenue. And two, it permits us to begin the process of educating physicians and engaging with them for the ultimate launch of Brensocatib in bronchiectasis, which is quite prevalent in Europe. So, we’re looking forward to where this – where we go with – from here, and we’ll take we’ll take their contribution in the next year, now that we have some of these approvals in hand.
Unidentified Analyst
Thank you. Thanks for taking the question.
Operator
The next the next question comes from Judah Frommer from Credit Suisse. Please go ahead.
Judah Frommer
Yes. Hi. Congrats on the progress, guys, and thanks for taking the questions. First, just on Q3 ARIKAYCE sales, I think it’s fair to say that they came in maybe a little better than internal expectations. Can you parse out whether that was US versus Japan, and maybe put your finger on what the benefits were in either one?
Will Lewis
Yes, I think just quickly what I would say is, the US continues to perform as it exits the COVID overpressure. Japan has struggled with the two headwinds it’s facing, but the fundamentals in the Japanese market are very strong. So, we can’t do anything about FX. An as Sara quantified, it’s quite a meaningful impact. And we can’t really do anything about COVID, except wait for it to clear. And we’ve seen in the US, as a precedent, that it takes some time for that to clear out and for everything to return back to normal. But when it does, the market reopens and we return to growth. So, I’m particularly excited about what we’re seeing in the US. The only constraint that I’m observing in the US, which was captured in a recent note, is the idea that physicians have pretty backed up calendars. And so, there are a lot of physicians who have a number of patients that are just going to be waiting to get an appointment. It’s hard to get access to a physician in the post-COVID world, particularly with a respiratory condition. So, I think that limits the degree to which we have a bolus of patients. Instead, it’s probably more of a slope of additional patients over time, at least that’s my expectation, but it’s a solid queue, and I think we’ll probably see the same thing in other regions around the world. But that’s probably the best color I can give you on US and Japan.
Judah Frommer
Okay, that’s helpful. And then just following up on the US, I guess as the asset matures and it’s been on the market for a couple of years here, anything you’re seeing in terms of real-world use, whether it’s maintenance dosing or re-treatment or potentially even off-label use in first line that you’re hearing about anecdotally that might be surprising to you? Or is everything kind of progressing as anticipated at launch?
Will Lewis
I think the most interesting development this year was the arrival in a steady fashion of the re-treatment of patients. So, what’s clear is that if you’ve had a good experience with ARIKAYCE and you get reinfected, as unfortunately is going to be the case for many of these patients, the instinct is to go back to that treatment because it was successful before. We know from our Phase 3 trial that that’s a good instinct to follow. The drug is very effective at keeping patients culture negative, and if they get reinfected, it is inevitably a new infection, not an old infection reappearing. So, that’s an encouraging piece of information for patients to understand, that if they’re getting retreated, they’re probably not going after the old infection. And to see that over – at a fairly steady pace over the last several quarters, tells us it’s real and it’s probably not going to go away. So, that’s one trend that I would highlight for attention and I think a positive one for us as we go forward. Beyond that, I don’t think there’s anything else I would comment on. I want to be really clear, we have no information, nor do we speak to folks about off-label treatment. I am aware that there’s a lot of appetite to want to use this and they obsess this market because of the data that came out of the American Thoracic Society a couple of years ago showing it’s very effective in treating that. But to get something advanced there on the regulatory front, would require a separate PRO and a separate trial, and that hurdle is one I don’t think we want to surmount. So, trends for the appropriate patients continue to be positive. I think we continue to see growth on the horizon, and I’m just really happy in the post-COVID world, how much things have snapped back to the way they were before COVID, and I think that bodes well for the future.
Judah Frommer
Thanks.
Operator
The next question comes from Joseph Schwartz from SVB Securities. Please go ahead, Joseph.
Joseph Schwartz
Hi. Thanks so much. So, on a fundamental basis in Japan, have you seen any benefit from the copay changes, which I believe started to take place in June? What do prescription dynamics look like for patients there now with respect to the drug and the device given, I think, some changes to the policy may have occurred? Is there any way to quantify what you’ve been seeing there for us?
Will Lewis
Yes. So, the challenge there, Joe, is with the other headwinds operating, in particular the COVID one, it makes it difficult to sort of tease out exactly what impact that may have had. I think as time goes forward, we’ll get a clearer picture on that. But it certainly gives the opportunity for patients to take a longer prescription from their physician. But in the current environment, it’s just too hard to discern that. I’m sorry I don’t have better information for you on that at this moment.
Joseph Schwartz
Okay, that’s understood. Thanks. And then on Brensocatib, given ASPEN is such a large study and it’s good to see is closing in on full enrollment, we were wondering if you can tell us about any things you’ve been doing to ensure that the right sites and patients are enrolled, and how you’ve been monitoring conduct there. Do you have any insight into how the trial’s been going on a blinded basis? And also, I was curious, how much are exacerbations generally influenced by seasonality in bronchiectasis? Have you seen any signs of that in WILLOW and/or ASPEN on a blinded basis?
Will Lewis
Yes. So, the conduct of the ASPEN study, I would say, is going exactly as we would have hoped and expected. We know, on a blinded blended basis, we look at this down to the country level on a weekly basis, the rate – blended rate of exacerbations in the trial. And I think the most important thing to take away is that this trial looks behaviorally very much like WILLOW did, and that is a point of comfort for us. We cross examine it a bunch of different ways, but right now, it looks a lot like WILLOW did, and that’s important because WILLOW was big enough and it studied the right endpoints, which are the same ones we’re going to be studying in Phase 3. So, we know what to look for and what good looks like within the trial on a blinded basis. We do see variability across the globe, as we would expect. If you look at recent meta studies that have been done, you see a lot of variability in respiratory trials. The key lessons from prior bronchiectasis studies, is that you have to have enough events in your trial to make sure that your drug, whatever it is, has the opportunity to perform. We have that in our trial. So, we feel very good about the event rate, what we’re seeing on a blended basis, again, being consistent with WILLOW. All signs point to, things are going as planned, and importantly, that we have the right patients in the study. And that’s why we – as we’ve always said, we prioritize quality first, speed second, and budget third when it comes to the execution of this trial. This is a landmark trial, and I think the fact that it’s a single study is another advantage. It reduces the variability of two different studies at two different times and all that that implies. And we’ve seen that in bronchiectasis previously. That’s a really good advantage for us. I would say that as a landmark trial, it has to stand the test of time and that is front and center in our minds as we go about executing this trial. We have just come from CHEST conference. We’ve come from the Infectious Disease Week conference. This is the talk of those conferences. It’s a very exciting time in the space because this is a very significant indication with nothing approved to treat it. And this drug is on the horizon of being able to reveal its data and potentially be the first ever approved therapy in the space.
Joseph Schwartz
Thank you for taking my questions.
Operator
The next question comes from Liisa Bayko from Evercore ISI. Please go ahead.
Liisa Bayko
Hi, there. Thanks for taking the question. First off, can you talk about the rollout of data for ARISE. How are we to interpret kind of any changes you make to the study or lack of changes, and how do we interpret what kind of is like good data from the ARISE study?
Will Lewis
Yes, it’s a fair question. I think the first thing we need to do is quantify, and let me just go into a little bit more detail here. When you think about a PRO and you’re looking at a particular measure, there’s sort of an assumed level of change within the measure that would represent something that’s clinically meaningful. Take for example, cough, as I mentioned before. Using the bronchiectasis questionnaire in the setting of bronchiectasis, this QOLB instrument that we have tailored for NTM, one would normally expect a around an eight-step change to be clinically meaningful in the setting of bronchiectasis. It’s not clear yet what would be considered clinically meaningful in NTM, but what I can tell you is that on a blended blinded basis, we’re already seeing changes in these measures in excess of that threshold. So, that is a very encouraging sign to know that we are seeing change in the patients, and that that is being captured by this instrument. We don’t know which arm they’re in. we don’t know any more detail than that. But to clear that hurdle and to know that we’re seeing change and it’s being tracked, is an important accomplishment, I think, already. What constitutes success? Pretty simple in my mind, topline results. Our arm needs to beat the other arm. And we’ll know that in the second half of next year once the PRO is validated. And we’ll know it across several different measures, not just the PRO, but also culture conversion, and also other measures beyond that, that are secondary and exploratory. So, we’ll have a range of data that should really spell out what is happening to patients on our combination of therapy versus the alternative, and what does that result in, in terms of their symptoms, how it makes them feel, as well as the impact on the presence or absence of the infection itself.
Historically, we’ve seen very good data on culture conversion, both overall levels and time to culture conversion. Those are important because they also inform the Japanese approval for frontline. And I think they will be very impactful on the US consideration as well. Just maybe take a side moment here to remind everybody. When this drug was first conditionally approved in the US for refractory, there was very little information, both about the disease and the impact of the drug. Today, we sit in a very different place. This drug has been on the market for three years in the US without any major issues or concerns. It has now been fully approved in Europe and fully approved in Japan without any restrictions. And that is a very different clinical picture and dataset, which the FDA will be evaluating when they think about whether it’s suitable for frontline use. So, yes, this trial is going to be important, but it doesn’t sit in isolation. It sits in the context of the broader experience of the drug. And this is considered widely, I think, at the FDA to be a case study of success in the approval of a novel antibiotic for the treatment of a disease that had nothing approved previously.
Liisa Bayko
Okay, great. Thanks, Will. And then – and just a question about the debt. You had some convertible notes as well, and you have this now new debt instrument. Can you talk about like how important is having a positive study in bronchiectasis for Brensocatib? Is that like key to kind of being able to address this debt? Maybe you can just talk about the – in the – like in the – let’s say the unfortunate circumstance that that trial doesn’t work out, like do you still have the wherewithal, do you think, to address the data just from this?
Will Lewis
I do, and we plan the alternative scenarios – yes, no, we plan the alternative scenarios all the time. We feel very good about our balance sheet and the capital structure we’ve taken on. When I think about what is going to be happening over the course of about the next year and a half, there is going to be a flywheel of clinical data readout that is positive. And that starts with ARISE, starts with really the CF data at the end of this year, the ARISE data next year, PHILD results, obviously ASPEN results. And then within that, the fourth pillar will be not only revealed, but will have both preclinical and clinical data. And I wouldn’t underestimate the punch that that fourth pillar will represent in terms of contribution to overall intrinsic value at the company. The plan here is pretty straightforward. We want all of these data points to be reading out in close enough proximity to one another that people begin to understand the scope of this company. And if there’s one idea I can leave you with it is to abandon the notion that this is an ARIKAYCE or a Brensocatib company. This is a four-pillar company, and each of these, we have conviction are going to read out in a positive way. And if that is the case, there will be a transformation of value in our view in terms of how this company is perceived and what it represents for shareholders.
Sara Bonstein
And if I could just add one other piece to that, the amount of diligence that our partners have done through this structured, also gives heightened level of confidence, I think, from an external perspective on that they wanted to put this capital to work after doing very thorough diligence on ARIKAYCE, on Brenso, and what it’s matched to offer.
Liisa Bayko
Was there any blended data offered for that group of people, out of curiosity?
Sara Bonstein
Are you speaking specifically on Brensocatib, Liisa?
Liisa Bayko
Yes.
Sara Bonstein
Yes. So, the thorough diligence was on ARIKAYCE, thorough diligence on Brensocatib. I can’t speak specifically as to what they had in the data room, but anything that we had, they had.
Liisa Bayko
Okay. All right. Thank you.
Operator
Our next question, council, Jennifer Kim from Cantor Fitzgerald. Please go ahead, Jennifer.
Jennifer Kim
Hey, everyone. Thanks for taking my questions. I have two here. The first is, with the step-up in OpEx we saw this quarter, could you give any color on what drove that and how we should think about things in the fourth quarter moving forward, given the New York Phase 2 studies plan for Brenso, and then bringing the fourth pillar forward and how we should think about that going forward? And then the second question is with the CF study for Brenso. I noticed earlier this month that the actual enrollment on clinical trials, so the actual enrollment was 34 patients versus the 48 expected, and then it was originally designed for a 50-50 split between the CFTR and non-CFTR patients, and that doesn’t seem to be the case any longer. And I was wondering if you could give any color around that. Thanks.
Will Lewis
So, I’ll take the second question first. The non-CFTR patients are fewer and far between, and it’s harder to get a hold of them. And it was thought by the folks that we consult with on this, that we didn’t need a 50-50 sample split, given the different populations, if you will, that are out there. So, the data we’ll have, will be more than adequate to give us the information we need. But it was just on the non-CFTR modulated patients that we had, I think some time ago made – reduced the number of patients that we were going to bring forward in that arm.
Sara Bonstein
And then the other clarifying point is, it was 36 to 48 patients. 48 assumed who went up to 65 dose. So, the – what we have completed is the 10, 25, and 40-milligram dose, and that’s the 34 patients that you’re seeing. And then, Jennifer, on your OpEx question, so what you see in our OpEx is you see continued support for all of our programs. TPIP now is underway and those Phase 2 programs, you’re seeing those spend levels included in OpEx. You’re seeing ASPEN and ARISE, ENCORE, full investment in those, some pre-launch, pre-commercialization activities for Brenso. You’re starting to see some of those expenses. We’re thoughtful on what do we need to spend today versus what can we wait to spend, while making sure that we’re prepared for a potential launch of almost a million patients at launch, assuming success with ASPEN. So, we’re thoughtful on our spend levels here and we’ll continue to be thoughtful, and you can see that through our development of waiting to start CRS until middle of next year, those types of activities.
Jennifer Kim
Okay. And if I could squeeze in one more question just on ARIKAYCE. I think before, you’ve talked about how Q3 seasonally is more modest versus the rest of the year. I’m just wondering, given the accelerated US growth we saw, did you experience whatever usually drives that seasonality this quarter, or is that something that could come up in the fourth quarter?
Will Lewis
It’s always hard to know what the difference is from one quarter to the next. We just – we sort of observe trends. The third quarter is usually impacted by people, for lack of a better way of saying it, just going on vacation and traveling, and they like to take holidays from their medicines during that time. But we didn’t – I don’t think we saw that in any great measure here that was above or below what our expectations were. And I don’t think it bears on in the fourth quarter.
Jennifer Kim
Okay. Thanks guys.
Operator
We have a follow up question from Ritu Baral from Cowen. Please go ahead, Ritu.
Unidentified Analyst
Hi. So, going back to the CF data that’s going to be reading out by year-end, is there a target level of neutrophil elastase inhibition that you’re aiming for in the readout?
Will Lewis
So, there’s not a specific target per se. What we’re going to be looking for is the impact of the drug on NSPs, is one of the measures we’re going to be looking at, and not just neutrophil elastase. It’s all the NSPs that we track, that we have assays for in both blood and sputum. So, that’s going to be what we look at. And what we saw in WILLOW, which was still very encouraging, was a dose-dependent relationship to the reduction in those NSPs, and then the reversal after discontinuing drug. So, success here would sort of replicate some of that behavior, even though it’s an abbreviated timeframe. It’s only 28 days. Nonetheless, we’re hopeful that we’ll see some of those similar trends here in a dose-dependent manner.
Unidentified Analyst
Okay. Thanks guys. Thank you.
Operator
It appears there’s no questions at this time. So, I’m just going to hand it back to the management team for final remarks.
Will Lewis
Perfect. Thank you very much for joining us today.
Operator
This concludes today’s call. Thank you for joining. You may now disconnect your lines.
Be the first to comment